The rest of the market is leaving Big Tech behind after a historic comeback

The market's leadership shifted in October: the Nasdaq Composite was down 1.4% through Tuesday, with chip stocks and some hyperscalers under pressure after the AI trade drove September gains. Struggling software stocks and consumer-staples and healthcare shares received a reprieve, while the average S&P 500 stock had a strong month.

Analysis

The key signal is relative leadership, not the modest headline-index move: if gains are spreading beyond a few mega-cap names, cap-weighted benchmarks may understate improving market breadth. That can support equal-weight exposure and reduce the index’s dependence on a narrow set of AI-linked earnings outcomes. But one month of rotation is not proof of durable participation; a reversal in chip and hyperscaler leadership could quickly restore concentration.

Over days to weeks, crowded-position unwinds can amplify moves in both directions, while flows into recently lagging defensives may be tactical rather than evidence of improving fundamentals. Over 1–3 months, earnings and guidance will test whether non-mega-cap participation is supported by revenue growth, or merely a relative escape from expensive growth. Over 6–18 months, sustained breadth would matter more than the monthly sector shuffle: it could broaden index returns, but would not by itself validate AI capex returns.

The contrarian risk is that investors extrapolate a short rotation into a structural regime change. Without breadth, flow, valuation, and earnings data, conviction should stay low. Falsification for a broadening thesis: the equal-weight S&P 500 underperforms the cap-weighted index again and leadership narrows, especially if chip and hyperscaler guidance reaccelerates.

Key Decisions for Investors

• Prefer a conditional relative-value expression over a broad market short: consider long RSP (S&P 500 equal-weight ETF) versus short SPY (cap-weighted S&P 500 ETF) only if the RSP/SPY ratio holds its October advance. Exit or stand aside if the ratio breaks below its October low; the main risk is a rapid rebound in mega-cap and semiconductor leadership.
• Do not chase defensive outperformance on this evidence alone. Treat consumer staples and healthcare as tactical hedges, not confirmed new leaders, until relative strength persists through the next earnings cycle.
• Keep AI exposure selective rather than treating the pullback as a sector-wide buy signal. Reassess semiconductor and hyperscaler risk against company-specific guidance and the durability of AI-related spending; a sustained deterioration in outlook would argue against buying the dip.
• Before increasing the breadth trade, verify equal-weight versus cap-weight performance, advance/decline participation, fund flows, and earnings-revision breadth. If those measures do not confirm the price rotation, make no trade rather than infer a durable trend from a single month.